Denali Therapeutics (DNLI) Institutional Ownership

During the previous two years, 219 institutional investors and hedge funds held shares of Denali Therapeutics. The most heavily invested institutionals were Baillie Gifford & Co. ($250.96M), Vanguard Group Inc. ($244.99M), Wellington Management Group LLP ($200.70M), FMR LLC ($163.44M), Temasek Holdings Private Ltd ($156.02M), State Street Corp ($123.86M), and Capital Research Global Investors ($111.63M).Learn more on DNLI's institutional investors.

92.92% of Denali Therapeutics stock is owned by institutional investors. Learn more on DNLI's institutional investor holdings.

Of the 185 institutional investors that purchased Denali Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: FMR LLC ($7.78M), Capital Research Global Investors ($3.54M), Norges Bank ($2.22M), Vanguard Group Inc. ($1.57M), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($1.45M), Point72 Asset Management L.P. ($1.27M), and Wellington Management Group LLP ($1.23M).

Institutional investors have bought a total of 35,790,546 shares in the last 24 months. This purchase volume represents approximately $862.99M in transactions.

Of the 99 institutional investors that sold Denali Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Baillie Gifford & Co. ($3.04M), ARCH Venture Management LLC ($2.98M), Capital Research Global Investors ($2.43M), Barclays PLC ($995.93K), Price T Rowe Associates Inc. MD ($979.99K), Wellington Management Group LLP ($893.74K), and Point72 Asset Management L.P. ($719.62K).

Institutional investors have sold a total of 17,692,447 shares in the last 24 months. This volume of shares sold represents approximately $420.81M in transactions.